The FDA has refused to approve Summit Therapeutics’ ivonescimab for lung cancer patients, blocking U.S. access to a therapy the company licensed for up to $5 billion. [1][2]
In late-stage testing, ivonescimab combined with chemotherapy reduced the risk of disease progression or death by 48% compared with chemotherapy alone, but the primary analysis did not show a statistically significant improvement in overall survival. [2]
The FDA said the drug’s progression-free survival benefit “in the absence of a statistically significant OS benefit” does not indicate a positive benefit-risk profile. [1]
“We are disappointed for patients and their families awaiting additional treatment options in this setting,” said Robert Duggan, co-CEO of Summit, in a Sunday statement. [1]
Summit acquired U.S., Canadian, European and Japanese rights to ivonescimab from China’s Akeso in 2022 under a deal valued at up to $5 billion; Akeso retained rights in China and other markets. [2]
TD Cowen analysts said earlier this month that a “subsequently matured OS dataset, consistency between Western and Asian patients, lack of new safety signals, and management’s previously characterized constructive regulatory interactions” strengthened the application versus its original analysis. [2]
Duggan said the company chose to pursue the ivonescimab regimen “based on the opportunity to provide another treatment option to help patients in need.” [1]



